Anthony Chalmers, MD, University of Glasgow, Glasgow, UK, discusses ongoing trials in the treatment of glioblastoma multiforme (GBM) and how PARP inhibitors coupled with radiotherapy may demonstrate the most optimal therapeutic response. Dr Chalmers also comments on the unique immunosuppressive environment created by the GBM tumor and how this has piqued interest in immune checkpoint inhibitors as a potential tumor-limiting strategy. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.